お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:セリンプロテインキナーゼ ATM:パイプライン製品の分析
市場調査レポート
商品コード
516020

セリンプロテインキナーゼ ATM:パイプライン製品の分析

Serine Protein Kinase ATM - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 34 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
セリンプロテインキナーゼ ATM:パイプライン製品の分析
出版日: 2020年07月31日
発行: Global Markets Direct
ページ情報: 英文 34 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、セリンプロテインキナーゼ ATMを標的とした治療薬の開発に関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

セリンプロテインキナーゼ ATM;概要

セリンプロテインキナーゼ ATM;治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AstraZeneca Plc
  • InteRNA Technologies BV
  • Shuttle Pharmaceuticals LLC

薬剤プロファイル

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by AstraZeneca Plc, H2 2020
  • Pipeline by IMPACT Therapeutics Inc, H2 2020
  • Pipeline by InteRNA Technologies BV, H2 2020
  • Pipeline by Merck KGaA, H2 2020
  • Pipeline by Shuttle Pharmaceuticals Inc, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC2549TDB

Summary:

According to the recently published report 'Serine Protein Kinase ATM - Pipeline Review, H2 2020'; Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends.

The report 'Serine Protein Kinase ATM - Pipeline Review, H2 2020' outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Breast Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Herpetic Keratitis and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
  • The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • IMPACT Therapeutics Inc
  • InteRNA Technologies BV
  • Merck KGaA
  • Shuttle Pharmaceuticals Inc
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles
  • Antisense RNAi Oligonucleotides to Inhibit ATM for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-1390 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Dormant Products
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Discontinued Products
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases
  • May 07, 2019: Xstrahl In Action: ATM inhibitors radiosensitize and improves survival of preclinical brain tumor models
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.